Kang et al., 2020 - Google Patents
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa FcγRIIIa V158 Mediates Reveals Potent That Antibody Ligation of Dependent Cellular …Kang et al., 2020
- Document ID
- 12551663767418779368
- Author
- Kang T
- Lee C
- Delidakis G
- Jung J
- Richard-Le Goff O
- Lee J
- Kim J
- Charab W
- Bruhns P
- Georgiou G
- Publication year
- Publication venue
- Roles of Fc Receptors in Disease and Therapy
External Links
Snippet
Kang et al. Contribution of FcγRIIIa in ADCP cancer cells, respectively, at a level comparable to that of the respective wild-type antibodies. We further show that hFcγRIIIa activation plays a significant role on ADCC by human peripheral monocytes. Our data highlight the utility of …
- 102000004965 antibodies 0 title abstract description 60
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102224556B1 (en) | Antibodies against T cell immune receptors (TIGIT) with IG and ITIM domains and their use | |
| Jefferis | Antibody therapeutics: isotype and glycoform selection | |
| Dahan et al. | Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement | |
| JP6840908B1 (en) | IgG1 Fc mutant with effector function removed | |
| EP3277725B1 (en) | Heavy chain constant regions with reduced binding to fc gamma receptors | |
| Kang et al. | An engineered human Fc variant with exquisite selectivity for FcγRIIIaV158 reveals that ligation of FcγRIIIa mediates potent antibody dependent cellular phagocytosis with GM-CSF-differentiated macrophages | |
| CN108368510B (en) | Agonistic antibodies that specifically bind to human CD40 and methods of use | |
| AU2014268298B2 (en) | Anti-B7-H5 antibodies and their uses | |
| EP2714733B1 (en) | Cd3-binding molecules capable of binding to human and non-human cd3 | |
| CN109475603A (en) | Anti- PD-L1 antibody | |
| US20220177585A1 (en) | Potency assays for antibody drug substance binding to an fc receptor | |
| Brandsma et al. | Fc receptor inside‐out signaling and possible impact on antibody therapy | |
| Park et al. | The highly evolvable antibody Fc domain | |
| JP2022513432A (en) | Bispecific antibodies for immune cell activation | |
| JP2023517252A (en) | Novel anti-LILRB4 antibodies and derived products | |
| KR20190128716A (en) | Anti-PD-L1 antibody and its use | |
| CA3124276A1 (en) | Humanized anti-pd-1 antibody and use thereof | |
| JP2023025215A (en) | Pd-l1 and ta-muc1 antibodies | |
| CN116234572A (en) | Therapeutic SIRP alpha antibodies | |
| US11639393B2 (en) | Anti-CCR8 antibodies | |
| JP2022514734A (en) | How to use anti-TREM2 antibody | |
| US8618251B1 (en) | Fc mutants | |
| Scallon et al. | Quantitative in vivo comparisons of the Fcγ receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody | |
| Kang et al. | An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa FcγRIIIa V158 Mediates Reveals Potent That Antibody Ligation of Dependent Cellular Phagocytosis With GM-CSF-Differentiated | |
| CN116194480A (en) | Method for redirecting IL-2 to target cells of interest |